1. Home
  2. CTRM vs LNAI Comparison

CTRM vs LNAI Comparison

Compare CTRM & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.11

Market Cap

21.1M

ML Signal

HOLD

Logo Lunai Bioworks Inc.

LNAI

Lunai Bioworks Inc.

N/A

Current Price

$0.91

Market Cap

21.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CTRM
LNAI
Founded
2016
N/A
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.1M
21.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CTRM
LNAI
Price
$2.11
$0.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
63.3K
254.9K
Earning Date
12-03-2025
02-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,412,579.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$0.81
52 Week High
$2.96
$14.00

Technical Indicators

Market Signals
Indicator
CTRM
LNAI
Relative Strength Index (RSI) 47.70 N/A
Support Level $2.09 N/A
Resistance Level $2.22 N/A
Average True Range (ATR) 0.11 0.00
MACD -0.02 0.00
Stochastic Oscillator 25.17 0.00

Price Performance

Historical Comparison
CTRM
LNAI

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments namely (i) the dry bulk segment (ii) the containership segment and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Share on Social Networks: